Biomarkers for Invasive Mucormycosis

计划入组 100 人 · 首次发布于 2022 年 6 月 6 日

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

计划入组 31 人 · 首次发布于 2019 年 1 月 25 日

Post Marketing Surveillance (PMS) Study of Cresemba in Korea.

计划入组 94 人 · 首次发布于 2021 年 2 月 9 日

Isavuconazonium(Cresemba)

C₃₅H₃₅F₂N₈O₅S

HER-096

Trivalent Invasive Salmonella Disease Vaccine(University of Maryland)

Orsi Academy

Belgium

Scynexis

United States

Venus Concept

United States

Cresemba Antifungal Drug Achieves Record Global Sales, Triggers $2.5M Milestone Payment to Basilea

Breakthrough Humanized Antibody VX-01 Shows Promise Against Deadly Mucormycosis

Basilea Receives $30 Million Milestone Payment as Cresemba Antifungal Sales Surge 27% Globally